CRA consultants were commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA) to conduct an independent and objective assessment of the impact on the life sciences industry in Europe of a withdrawal of the United Kingdom from the European Union (commonly described as British exit from the EU or “Brexit”). The broad goal of this project was to identify, from both a UK and a European perspective, the positive and negative impact that a change in the relationship might have upon activities along the industry’s value chain.
To read the report, click the link below.
Inequities in patient support, well-being, and treatment access for triple negative breast cancer patients
In this report, Charles River Associates (CRA) and Cancer Support Community (CSC) examine the extent to which policies associated with long-term support,...